Compare BLIN & IRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLIN | IRIX |
|---|---|---|
| Founded | 2000 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.6M | 15.0M |
| IPO Year | 2018 | 1996 |
| Metric | BLIN | IRIX |
|---|---|---|
| Price | $1.00 | $0.88 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.62 | N/A |
| AVG Volume (30 Days) | ★ 58.2K | 45.2K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.85 |
| EPS | N/A | ★ N/A |
| Revenue | $13,568,000.00 | ★ $41,593,000.00 |
| Revenue This Year | $22.67 | $3.07 |
| Revenue Next Year | $21.08 | $6.66 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.69 | $0.80 |
| 52 Week High | $1.59 | $1.65 |
| Indicator | BLIN | IRIX |
|---|---|---|
| Relative Strength Index (RSI) | 35.27 | 47.43 |
| Support Level | $0.93 | $0.88 |
| Resistance Level | $1.05 | $1.17 |
| Average True Range (ATR) | 0.08 | 0.05 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 8.70 | 71.30 |
Bridgeline Digital Inc is a AI-powered marketing technology company that offers a suite of products that help companies grow online revenue by driving more traffic to their websites, converting more visitors to purchasers, and increasing average order value. Company software is available through a cloud-based Software as a Service (SaaS) model. It helps to maximize the performance of critical websites, intranets, and online stores. The company generates revenue from digital engagement services, subscription, perpetual licenses, maintenance, and hosting. Geographically, it derives a majority of revenue from the United States.
IRIDEX Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.